title: Standard therapy for patients with myelodysplastic syndromes.
abstract: The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders characterized by cytopenias, dysplastic changes in the hematopoietic precursors, and an increased risk of evolving into acute leukemia. Treatment for patients with MDS ranges from supportive care with blood products and/or growth factors up to allogeneic stem cell transplantation. Over the past decade, several novel therapeutic agents have been approved for clinical use. In this article, the current approach for the management of patients with MDS according to their risk category is described and mainly focuses on approved novel agents.
authors.affiliation: Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX 77030, USA.
authors.forename: Ali
authors.initials: A
authors.lastname: Al-Ameri
authors.forename: Mohamad
authors.initials: M
authors.lastname: Cherry
authors.forename: Guillermo
authors.initials: G
authors.lastname: Garcia-Manero
authors.forename: Alfonso
authors.initials: A
authors.lastname: Quintás-Cardama
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D019175:DNA Methylation / Q000187:drug effects; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D036341:Intercellular Signaling Peptides and Proteins / Q000627:therapeutic use*; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D008020:Life Support Care; D009190:Myelodysplastic Syndromes / Q000628:therapy*; D011379:Prognosis
chemical_list: D020533:Angiogenesis Inhibitors; D007166:Immunosuppressive Agents; D036341:Intercellular Signaling Peptides and Proteins; D007502:Iron Chelating Agents